Alicja, I understand the concept of “off label
Post# of 148300
I understand the concept of “off label”, but wanted to clarify your comment....the patient will be at insurance discretion for coverage until sBLA is approved? At any point prior to this, insurance provider has sole determination? If so, my thought doesn’t change as much as I would like it to....insurance is in a business and unless they can save money (which mono at $120, $70k or even at $24k may not) then would they agree to pay for an unapproved treatment? If pivotal is approved soon then “off label” is a moot point, but I’m just want to be realistic with my expectations? I’m really surprised Fine is selling this concept, or maybe I’m still missing something?